AM
DGX icon

Atwater Malick’s Quest Diagnostics DGX Stock Holding History

Atwater Malick’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.94M Sell
30,316
-5,017
-14% -$975K 1.6% 17
2025
Q4 		$6.13M Sell
35,333
-7,609
-18% -$1.39M 1.69% 17
2025
Q3 		$8.18M Sell
42,942
-13,724
-24% -$2.44M 2.38% 15
2025
Q2 		$10.2M Buy
56,666
+18
+0% +$3.13K 3.22% 13
2025
Q1 		$9.58M Buy
56,648
+1,512
+3% +$248K 3.24% 14
2024
Q4 		$8.32M Sell
55,136
-473
-0.9% -$73.6K 2.79% 14
2024
Q3 		$8.63M Buy
55,609
+670
+1% +$100K 2.78% 16
2024
Q2 		$7.52M Buy
54,939
+190
+0.3% +$26K 2.59% 17
2024
Q1 		$7.29M Buy
54,749
+779
+1% +$101K 2.57% 19
2023
Q4 		$7.44M Buy
53,970
+1,244
+2% +$164K 2.92% 16
2023
Q3 		$6.43M Buy
52,726
+634
+1% +$84.5K 2.83% 16
2023
Q2 		$7.32M Buy
52,092
+1,715
+3% +$236K 3.13% 16
2023
Q1 		$7.13M Buy
50,377
+734
+1% +$105K 3.34% 15
2022
Q4 		$7.77M Buy
49,643
+845
+2% +$121K 3.83% 14
2022
Q3 		$5.99M Buy
48,798
+1,264
+3% +$166K 3.35% 18
2022
Q2 		$6.32M Buy
47,534
+1,110
+2% +$151K 3.33% 16
2022
Q1 		$6.35M Buy
46,424
+2,342
+5% +$326K 3.07% 20
2021
Q4 		$7.63M Buy
44,082
+706
+2% +$107K 3.54% 12
2021
Q3 		$6.3M Buy
43,376
+977
+2% +$143K 3.33% 14
2021
Q2 		$5.59M Buy
42,399
+2,944
+7% +$385K 3.09% 19
2021
Q1 		$5.06M Sell
39,455
-2,081
-5% -$256K 3.11% 19
2020
Q4 		$4.95M Buy
41,536
+395
+1% +$48.2K 3.11% 18
2020
Q3 		$4.71M Buy
41,141
+745
+2% +$88K 3.3% 16
2020
Q2 		$4.6M Buy
40,396
+1,831
+5% +$194K 3.62% 13
2020
Q1 		$3.1M Buy
38,565
+2,517
+7% +$261K 2.97% 21
2019
Q4 		$3.85M Buy
36,048
+1,399
+4% +$146K 3.06% 22
2019
Q3 		$3.71M Buy
34,649
+1,575
+5% +$162K 3.11% 21
2019
Q2 		$3.37M Buy
33,074
+894
+3% +$85.9K 3.09% 21
2019
Q1 		$2.89M Buy
32,180
+3,447
+12% +$299K 2.83% 22
2018
Q4 		$2.39M Buy
+28,733
New +$2.69M 2.68% 24

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Atwater Malick's DGX Position: Q1 2026 in Review

Atwater Malick reduced its Quest Diagnostics (DGX) stake by 14% in Q1 2026, selling an estimated $975K and leaving 30,316 shares worth $5.94M. The position accounts for 1.6% of the portfolio, ranked #17.

Atwater Malick first reported a position in DGX in Q4 2018 and has held it in 30 quarters since. The position peaked at $10.2M in Q2 2025. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Atwater Malick held 30,316 shares of Quest Diagnostics worth $5.94M as of Q1 2026.
  • Atwater Malick sold 5,017 Quest Diagnostics shares in Q1 2026, an estimated $975K.
  • Quest Diagnostics made up 1.6% of Atwater Malick's portfolio in Q1 2026, its #17 holding.
  • Atwater Malick first reported a position in Quest Diagnostics in Q4 2018 and has held it in 30 quarters since.
  • Atwater Malick's Quest Diagnostics position peaked at $10.2M in Q2 2025.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Atwater Malick's 13F filing for Q1 2026, filed 22 Apr 2026.